Applied Therapeutics, Inc. (APLT) Dividend History

Company News

• Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

  Applied Therapeutics presented positive 12-month and 24-month data from its INSPIRE trial of govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), a rare neuromuscular disease. The data showed significant reductions in blood sorbitol levels and improvements in functional and patient-reported outcomes.

  GlobeNewswire Inc.
• All You Need to Know About Applied Therapeutics Rating Upgrade to Buy

  Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. This positive outlook is expected to have a favorable impact on the stock price.

  Benzinga
• Why Applied Therapeutics Stock Is Skyrocketing Today

  The FDA has canceled the Advisory Committee meeting to review Applied Therapeutics' New Drug Application for govorestat, a drug to treat galactosemia. This increases the likelihood of FDA approval, leading to a 70.5% surge in Applied Therapeutics' stock price.

  The Motley Fool
• G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates

  G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -5.26% and 4.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research
• 3 Penny Stocks To Buy According To Insiders In December

  3 top penny stocks to watch with insider buying this month. The post 3 Penny Stocks To Buy According To Insiders In December appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: ERAS GBIO